The emerging technology of transcatheter aortic valve replacement (TAVR) offers a chance at a longer life for some patients with inoperable aortic stenosis. But with the “indication creep” that often seems to follow approval of a new device or drug by the US Food and Drug Administration (FDA), some researchers worry that TAVR could end up causing more harm than benefit when used in patients with less risky aortic stenosis.
Mitka M. Caution Urged in Ramping Up Use of Transcatheter Aortic Valve Replacement. JAMA. 2012;308(10):962-963. doi:10.1001/2012.jama.10941